Capital Holdings Grow
Fieldview Capital Expands Holdings Across Diverse Stocks, Reflecting Broader Institutional Reassessment
Key Points
For Royalty Pharma (RPRX), Fieldview’s 4th-quarter new position was 96,752 shares valued at about $3.738 million, and the filing context notes institutional ownership at 54.35%. The report also highlights specific analyst actions: Weiss Ratings downgraded from “buy (b)” to “buy (b-)” (May 15) while Morgan Stanley raised its price target from $61 to $63 and maintained an “overweight” rating (April 10).
In International Paper (IP), Fieldview increased its stake by 154.0% to 74,794 shares (adding 45,344), worth $2.946 million. The article adds a company-insider detail: Director Scott Tozier bought 10,000 shares at an average $31.30 on May 1 for about $313,000, and the report states hedge funds and other institutional investors own 81.95% of the stock.
For PBF Energy (PBF), Fieldview’s stake was lifted by 548.1% to 81,873 shares after adding 69,241, valued at $2.22 million. The report further notes that 96.29% of the stock is held by hedge funds and other institutional investors, and includes a specific analyst move: Mizuho raised its price target from $43 to $48 while keeping a “neutral” rating (May 27).
In Texas Capital Bancshares (TCBI), Fieldview increased its position by 56.1% to 44,084 shares (adding 15,848). The report specifies the position size (about 0.10% of the company, worth $3.991 million) and that institutional investors own 96.88% of the stock. It also records analyst divergence: Citigroup raised its target from $88 to $96 but kept a “sell” rating (April 28), while Zacks cut from “strong-buy” to a “hold” (March 30).
Fieldview Capital Management LLC has sharply expanded its bets across four major stocks, SEC filings show. The firm built a brand-new position in Royalty Pharma, more than doubled its International Paper stake, and nearly sextupled its PBF Energy holding in the fourth quarter, according to Watchlist News and Ticker Report.
The moves span sectors from healthcare royalties and paper packaging to oil refining and regional banking. Across all four names, institutional investors dominate the ownership — in some cases holding nearly the entire float.
Fieldview Enters Royalty Pharma, Doubles Down on Paper
Fieldview opened a fresh position in Royalty Pharma (RPRX), buying 96,752 shares worth about $3.74 million, per Watchlist News. Royalty Pharma owns the rights to future cash flows from blockbuster drugs. It operates like a hybrid between a private equity firm and a pharmaceutical company. Institutional investors currently hold 54.35% of the stock.
In International Paper (IP), Fieldview raised its stake by 154.0%, adding 45,344 shares to reach 74,794 total, worth $2.95 million, according to Ticker Report. That move came alongside an insider buy. IP Director Scott Tozier purchased 10,000 shares at $31.30 each on May 1, spending roughly $313,000 of his own money. Institutional investors own 81.95% of IP.
PBF Energy Stake Jumps 548% in a Single Quarter
The boldest move was in PBF Energy (PBF), an independent oil refiner. Fieldview added 69,241 shares, lifting its total to 81,873 — a 548.1% increase. The position is now worth $2.22 million. Hedge funds and institutional investors already own 96.29% of PBF's stock, making it one of the most institutionally crowded names in the group.
The bet appears to be a wager on refining margins staying high. Mizuho raised its PBF price target from $43 to $48 on May 27 but kept a
neutral
rating, suggesting Wall Street analysts are still cautious even as Fieldview pushes in aggressively.
Texas Capital Bancshares Draws Conflicting Analyst Views
Fieldview also grew its Texas Capital Bancshares (TCBI) position by 56.1%, adding 15,848 shares for a total of 44,084. That stake is worth about $3.99 million and equals roughly 0.10% of the company. Institutional investors hold 96.88% of TCBI — leaving almost no shares in retail hands.
Analysts are sharply divided on the bank. Citigroup raised its price target from $88 to $96 on April 28 but kept a
sell
rating — essentially telling clients to exit into any strength. Meanwhile, Zacks cut TCBI from
strong-buy
to
hold
on March 30. Fieldview's decision to add shares despite those warnings signals a high-conviction contrarian stance on Texas regional banking.
Morgan Stanley Backs Royalty Pharma as Rating Agencies Cool
Not all analyst signals are cautious. Morgan Stanley raised its Royalty Pharma price target from $61 to $63 on April 10 and kept an
overweight
rating, pointing to the company's strong cash flow potential. That bullish view lines up directly with Fieldview's decision to open its $3.74 million position in RPRX.
Still, smaller rating firms are trimming their enthusiasm. Weiss Ratings downgraded RPRX from
Buy (b)
to
Buy (b-)
on May 15 — a mild step down that suggests the easy gains may already be priced in. Together, the filings paint a picture of Fieldview leaning into sectors where big institutional names are cautious, betting that the market has underpriced both the healthcare royalty model and old-economy cyclical stocks like paper and refining.
Sentiment
Mostly PositivePublishers
23
Articles
10
Reach
33
